Erlanger Health, Inc.,

Chattanooga, Tennessee 37403

5 studies enrolling now · 7 studies all time

What they study most

Atrial Fibrillation, Bleeding, Cardiovascular Disease, Endometrioid Ovarian Cancer, Fallopian Tube Cancer, High-grade Serous Ovarian Cancer, NMIBC, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Platinum-refractory Ovarian Cancer, Platinum-resistant Ovarian Cancer, Prevention of Stroke or Systemic Embolism

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) — Recruiting now
• Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — Recruiting now
• ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer — Available (expanded access)
• HEAL-LAA Clinical Trial — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early